Market Trends of Antibody Production Industry
This section covers the major market trends shaping the Antibody Production Market according to our research experts:
The Monoclonal Antibodies Segment is Expected to Hold a Significant Market Share Over The Forecast Period
Monoclonal antibodies have large applications in diagnostics, therapeutics, and targeted drug delivery systems, not only for infectious diseases caused by bacteria, viruses, and protozoa but also for cancer, metabolic, and hormonal disorders.
The segment is expected to hold a significant market share during the forecast period, owing to the rising investment in monoclonal antibody research and an increase in antibody-based product launches. For instance, according to an article published in the Journal of Biomedical Sciences in January 2022, monoclonal antibodies (mAbs) emerged as powerful tools to treat and detect numerous diseases because of their high specificity and reliability. This characteristic has urged the demand for several research studies in which monoclonal antibodies were used for COVID-19 therapy and SARS-CoV-2 detection. Thus, the utility of monoclonal antibodies is immense, ranging from cancer to osteoporosis and organ transplant rejection, which is estimated to propel segment growth.
Furthermore, the strategic initiatives adopted by pharma and biotech companies, such as rising research and development leading to product approvals and launches and a growing collaboration to develop advanced monoclonal antibodies, are also fueling the segment growth. For instance, in May 2021, Cipla launched Roche's antibody cocktail (Casrivimab and Imdevimab) in India for the treatment of mild- to moderate COVID-19 in adults and pediatric patients (12 years of age or older weighing at least 40 kg). Additionally, global pharmaceutical companies are investing heavily in the R&D of cancer biologics drugs (monoclonal antibodies) because they are very efficient and non-toxic in the diagnostics and treatment of different types of cancer as compared to chemotherapy and other cancer treatment methods. These factors are expected to fuel the growth of the monoclonal antibodies segment in the coming years.
North America is Expected to Hold a Significant Market Share Over The Forecast Period
North America is expected to hold a significant share of antibody production owing to the high prevalence of cancer in the region and the strong presence of favorable healthcare infrastructure, and innovations and product launches by market players in the region.
According to the American Cancer Society Cancer Statistics 2022, 1,918,030 new cancer cases are predicted to occur in the United States in 2022. Out of the total cancer cases, breast cancer is estimated for 290,560 new cases, leukemia with 60,650 new cases, and lymphoma with 89,010 new cases in the United States in 2022. Additionally, according to the Canadian Cancer Statistics November 2021 report, an estimated 2 in 5 Canadians were likely to be diagnosed with cancer in their lifetime. It stated that an estimated 229,200 Canadians was predicted to be diagnosed with cancer in 2021.
Furthermore, there is a rise in the approval of antibodies for the treatment of cancer and various types of diseases, which is also contributing to the market growth in the region. For instance, in February 2022, the U.S. FDA issued an emergency use authorization (EUA) for a new monoclonal antibody for bebtelovimab used for the treatment of COVID-19 that retains activity against the omicron variant. The EUA was for the treatment of mild to moderate COVID-19 in adults and pediatric COVID-19-positive patients. The EUA for monoclonal antibodies is expected to create opportunities for pharmaceutical and biotechnology companies to expedite their research and development on the antibodies to develop an innovative treatment, thereby propelling market growth in the region.
Moreover, the antibody production expansion by key players in the region is also fuelling market growth. For instance, in July 2021, Cytiva and Pall Corporation signed a collaboration agreement for the expansion of manufacturing capacity and services across geographies to meet the growing demand for biotechnology solutions. Cytiva and Pall Corporation's capacity expansion will increase the manufacture of key products used to make biological medicines which are ultimately estimated to propel antibody production in the region during the forecast period.
